Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study

Leila Khoja(AstraZeneca (United Kingdom)), Anthony M. Joshua(St Vincent's Hospital Sydney), Ahmad A. Tarhini(UPMC Hillman Cancer Center), Claudia Pfoehler(MSH Medical School Hamburg – University of Applied Sciences and Medical University), F. Mouriaux(Inserm), L.B.J. van Iersel(Maastricht University Medical Centre), Serge Leyvraz(Humboldt-Universität zu Berlin), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Sapna P. Patel(JSS Dental College and Hospital), Thomas J. Vogl(Goethe University Frankfurt), Poulam M. Patel(Nottingham University Hospitals NHS Trust), Nicolas Penel(Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail), Takami Sato(Thomas Jefferson University), I. Jolanda M. de Vries(Radboud University Nijmegen), Eshetu G. Atenafu(Princess Margaret Cancer Centre), Tina Cheng(University of Calgary), Lisa Zimmer(The University of Sydney), Ulrich Keilholz(German Cancer Research Center), Giammaria Fiorentini(Ospedali Riuniti Marche Nord), Stefan Suciu(St James's University Hospital), Peter Huppert(Klinikum Darmstadt), Tero Kivelä(University of Helsinki), Richard D. Carvajal(Northwell Health), Sophie Piperno‐Neumann(Institut Curie), E. Marshall(Clatterbridge Cancer Centre NHS Foundation Trust), Josep M. Piulats(Institut Català d'Ornitologia)

Annals of Oncology

May 28, 2019

Cited by 282

|New England Journal of Medicine|2012|12.6k

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2014|3k

|New England Journal of Medicine|2012|2.8k

|Journal of Clinical Oncology|2014|2.2k

Related Papers